Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris

FMX101 4% minocycline is a hydrophobic, topical foam formulation of minocycline recently approved by the United States Food and Drug Administration (FDA) for the treatment of non-nodular inflammatory lesions in moderate-to-severe acne vulgaris. It was developed to harness the anti-inflammatory and a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Aesthet Dermatol
Autori principali: Kircik, Leon, Del Rosso, James Q, Weiss, Jonathan S, Stakias, Vassilis, London, Anat, Keynan, Rita, Hazot, Yohan, Elliott, Russell, Stuart, Iain
Natura: Artigo
Lingua:Inglês
Pubblicazione: Matrix Medical Communications 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7605387/
https://ncbi.nlm.nih.gov/pubmed/33144907
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi